Request Free Sample ×
Artificial Pancreas Device System Market Research Report–Forecast till 2035 Infographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Artificial Pancreas Device System Market

ID: MRFR/MED/5208-HCR
100 Pages
Rahul Gotadki
Last Updated: April 06, 2026

Artificial Pancreas Device System Market Research Report: Size, Share, Trend Analysis By Types (Fully Automated, Semi-Automated, Transcutaneous), By Component (Glucose Sensor, Insulin Pump, Control Algorithm), By End Users (Hospitals, Home Care Settings, Diabetes Clinics), By Technology (Closed Loop Systems, Open Loop Systems, Hybrid Systems) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Artificial Pancreas Device System Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Methodology Download PDF

Artificial Pancreas Device System Market Summary

As per Market Research Future analysis, the Artificial Pancreas Device System Market was estimated at 1.233 USD Billion in 2024. The Artificial Pancreas Device System industry is projected to grow from 1.476 USD Billion in 2025 to 8.93 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 19.72% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The Artificial Pancreas Device System Market is poised for substantial growth driven by technological advancements and increasing diabetes prevalence.

  • North America remains the largest market for artificial pancreas devices, reflecting a strong demand for diabetes management solutions.
  • The Asia-Pacific region is emerging as the fastest-growing market, driven by rising diabetes cases and increasing healthcare investments.
  • Fully automated systems dominate the market, while semi-automated systems are experiencing rapid growth due to advancements in technology.
  • Key market drivers include technological advancements and regulatory support, which are essential for fostering innovation and accessibility.

Market Size & Forecast

2024 Market Size 1.233 (USD Billion)
2035 Market Size 8.93 (USD Billion)
CAGR (2025 - 2035) 19.72%

Major Players

Medtronic (US), Insulet Corporation (US), Tandem Diabetes Care (US), Roche Diabetes Care (DE), Dexcom (US), Abbott Laboratories (US), Ypsomed (CH), AstraZeneca (GB), Boehringer Ingelheim (DE)

Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry

Artificial Pancreas Device System Market Trends

The Artificial Pancreas Device System Market is currently experiencing a transformative phase, supported by evolving artificial pancreas device system market trends, driven by advancements in technology and increasing awareness of diabetes management across the artificial pancreas device systems market. The integration of artificial intelligence and machine learning into these devices appears to enhance their functionality, allowing for more precise glucose monitoring and insulin delivery. This evolution suggests a shift towards more personalized treatment options, which could significantly improve patient outcomes. Furthermore, the growing prevalence of diabetes worldwide is likely to fuel demand for innovative solutions that simplify management and improve quality of life for individuals living with this condition, thereby strengthening the artificial pancreas device system apds market landscape.

In addition to technological advancements, regulatory support is becoming increasingly evident, as governments and health organizations recognize the potential benefits of artificial pancreas systems. This support may lead to expedited approvals and increased funding for research and development within the artificial pancreas devices systems market. As a result, the market is poised for substantial growth, with new entrants and established companies alike striving to capture market share. The convergence of technology, regulatory support, and rising patient needs indicates a promising future for the Artificial Pancreas Device System Market, potentially leading to enhanced accessibility and affordability of these life-changing devices.

Technological Advancements

The integration of cutting-edge technologies, such as artificial intelligence and machine learning, is revolutionizing the Artificial Pancreas Device System Market and accelerating artificial pancreas device system market growth. These innovations enable more accurate glucose monitoring and insulin delivery, fostering personalized treatment approaches that cater to individual patient needs.

Regulatory Support

Increasing recognition from regulatory bodies regarding the benefits of artificial pancreas systems is shaping the market landscape. This support may facilitate faster approvals and encourage investment in research and development, ultimately enhancing the availability of these devices across the global artificial pancreas device systems market.

Rising Diabetes Prevalence

The growing incidence of diabetes globally is driving demand for effective management solutions within the artificial pancreas device system market. As more individuals seek advanced technologies to assist in their daily management, the market is likely to expand, offering innovative options for improved patient care.

Artificial Pancreas Device System Market Drivers

Regulatory Support

Regulatory support plays a crucial role in the growth of the Artificial Pancreas Device System Market. Regulatory bodies are increasingly recognizing the importance of these devices in diabetes management, leading to streamlined approval processes. This support not only accelerates the introduction of innovative products but also instills confidence among manufacturers and consumers alike. Recent initiatives by regulatory agencies to establish clear guidelines for the development and testing of artificial pancreas systems suggest a commitment to fostering innovation in this field. As a result, the market is likely to see a surge in new entrants and product offerings, which could enhance competition and drive down costs for consumers.

Rising Diabetes Prevalence

The rising prevalence of diabetes worldwide is a significant driver for the Artificial Pancreas Device System Market. With millions of individuals diagnosed with diabetes, the demand for effective management solutions is at an all-time high. Data indicates that the number of people living with diabetes is expected to reach 700 million by 2045, creating an urgent need for advanced treatment options. The artificial pancreas systems offer a promising solution by automating insulin delivery and monitoring blood glucose levels, thereby improving patient outcomes. This increasing patient population is likely to propel market growth, as healthcare providers seek to implement more efficient diabetes management strategies.

Technological Advancements

The Artificial Pancreas Device System Market is experiencing rapid technological advancements that enhance device functionality and user experience. Innovations such as continuous glucose monitoring and automated insulin delivery systems are becoming more sophisticated, allowing for better glycemic control. The integration of artificial intelligence and machine learning algorithms into these devices is likely to improve predictive capabilities, thus reducing the risk of hypoglycemia and hyperglycemia. According to recent data, the market for these advanced systems is projected to grow significantly, with estimates suggesting a compound annual growth rate of over 20% in the coming years. This trend indicates a strong demand for more efficient and user-friendly devices, which could potentially transform diabetes management for millions of patients.

Increased Awareness and Education

Increased awareness and education regarding diabetes management are pivotal in driving the Artificial Pancreas Device System Market. As healthcare professionals and patients become more informed about the benefits of advanced diabetes technologies, the adoption rates of artificial pancreas systems are expected to rise. Educational initiatives aimed at both patients and healthcare providers are likely to enhance understanding of how these devices can improve quality of life and reduce complications associated with diabetes. This heightened awareness may lead to greater acceptance and utilization of artificial pancreas systems, ultimately contributing to market expansion.

Investment in Research and Development

Investment in research and development is a key factor propelling the Artificial Pancreas Device System Market. As companies strive to innovate and improve existing technologies, substantial funding is being directed towards R&D efforts. This investment is likely to yield breakthroughs in device design, functionality, and user interface, making artificial pancreas systems more accessible and effective for patients. Furthermore, collaborations between academic institutions and industry players are fostering an environment conducive to innovation. The anticipated advancements resulting from these investments could significantly enhance the capabilities of artificial pancreas systems, thereby attracting more users and driving market growth.

Market Segment Insights

By Type: Fully Automated (Largest) vs. Semi-Automated (Fastest-Growing)

In the Artificial Pancreas Device System Market, the Fully Automated segment holds the largest share due to its advanced technology and ease of use, contributing significantly to overall artificial pancreas device system market share. This segment is recognized for providing users with a seamless experience in managing diabetes, as it automates insulin delivery completely. Conversely, the Semi-Automated segment, while smaller in market share, is gaining traction among users for its balance of automation and manual control, appealing to varying degrees of user comfort and preference. Recent trends suggest robust growth in the Semi-Automated segment, driven by consumer demand for customizable solutions and the increased focus on personalized healthcare, further influencing positive artificial pancreas device system market trends. Additionally, technological advancements and research initiatives aimed at enhancing the usability and efficacy of these systems contribute to expanding both the Fully Automated and Semi-Automated segments in the market.

Technology: Fully Automated (Dominant) vs. Semi-Automated (Emerging)

The Fully Automated segment is characterized by its ability to independently regulate insulin delivery based on real-time glucose monitoring, providing a comprehensive solution for diabetes management within the artificial pancreas device system market. Users appreciate the convenience and reliability of these systems, leading to high adoption rates. On the other hand, the Semi-Automated segment offers a hybrid approach, allowing users to manually adjust insulin doses while benefiting from automated features. This appeals to those who value control and flexibility in their treatment. As healthcare providers increasingly recognize the need for tailored solutions, both segments are poised to adapt and innovate, enhancing patient outcomes and driving overall artificial pancreas device system market growth.

By Component: Glucose Sensor (Largest) vs. Control Algorithm (Fastest-Growing)

The Artificial Pancreas Device System Market is primarily driven by three key components: Glucose Sensor, Insulin Pump, and Control Algorithm. Among these, Glucose Sensors hold the largest market share, reinforcing their role in the artificial pancreas device system market size expansion. Insulin Pumps follow, enabling users to manage insulin delivery efficiently. The Control Algorithm, while currently smaller in share, is gaining traction due to advancements in technology and the increased emphasis on precise insulin delivery systems.

Glucose Sensor (Dominant) vs. Control Algorithm (Emerging)

The Glucose Sensor is the dominant component within the Artificial Pancreas Device System Market, playing a critical role in ensuring consistent and accurate glucose monitoring. This technology focuses on real-time glucose data, allowing for timely insulin delivery adjustments. In contrast, the Control Algorithm is an emerging component designed to interpret data from glucose sensors to enhance insulin delivery's responsiveness. This segment is rapidly growing, driven by continuous innovations that improve device accuracy and personalization of diabetes management, making it a vital part of future advances in artificial pancreas technologies.

By End User: Hospitals (Largest) vs. Diabetes Clinics (Fastest-Growing)

The Artificial Pancreas Device System Market is prominently influenced by the end user segment distribution. Hospitals represent the largest share of this market segment, as they are equipped with advanced technologies and skilled personnel to manage complex cases of diabetes. Home care settings also play a significant role, offering convenience and accessibility for patients requiring regular monitoring and care. Diabetes clinics, while smaller in share, are rapidly expanding due to increasing demand for specialized services and patient education, making them a vital component of the market.

Hospital (Dominant) vs. Diabetes Clinics (Emerging)

Hospitals dominate the Artificial Pancreas Device System Market due to their ability to provide comprehensive care and quick access to advanced technologies. They offer a range of specialized services, ensuring effective management of diabetes patients through trained healthcare professionals. On the other hand, Diabetes clinics are emerging as a crucial component of the healthcare system, focusing on personalized care and patient education. These clinics are gaining traction as more individuals seek tailored treatments, resulting in a rising demand for artificial pancreas systems. This shift underscores the need for accessibility to innovative diabetes solutions, positioning diabetes clinics as key players in the industry's future.

By Technology: Closed Loop Systems (Largest) vs. Hybrid Systems (Fastest-Growing)

In the Artificial Pancreas Device System Market, Closed Loop Systems hold the largest market share due to their advanced functionalities in automating insulin delivery. This system significantly improves glycemic control among diabetes patients, making it a preferred choice for many healthcare professionals. Hybrid Systems, while currently smaller in share, show immense potential in the market as they offer a blend of automated and manual insulin delivery, catering to a diverse patient population.

Technology: Closed Loop Systems (Dominant) vs. Hybrid Systems (Emerging)

Closed Loop Systems are characterized by their ability to continuously monitor glucose levels and automatically administer insulin, providing a seamless experience for users. They are considered the dominant technology in the market due to their effectiveness and reliability. On the other hand, Hybrid Systems play an emerging role, as they combine features of both closed and open loop systems. This adaptability makes them appealing for patients who desire more control over their diabetes management while still benefiting from automation. As technology continues to evolve, the relevance of both systems will likely increase in various patient scenarios.

Get more detailed insights about Artificial Pancreas Device System Market
Request Free Sample

Regional Insights

North America : Market Leader in Innovation

North America is the largest market for Artificial Pancreas Device Systems, holding approximately 45% of the global market share. The region benefits from advanced healthcare infrastructure, high diabetes prevalence, and significant investments in research and development. Regulatory support from agencies like the FDA has accelerated the approval of innovative devices, driving demand for advanced diabetes management solutions. The United States is the primary contributor, with key players such as Medtronic, Insulet Corporation, and Dexcom leading the competitive landscape. The presence of established healthcare systems and a growing focus on personalized medicine further enhance market growth. The competitive environment is characterized by continuous innovation and strategic partnerships among leading companies, ensuring a robust supply of advanced devices to meet rising patient needs.

Europe : Emerging Market with Growth Potential

Europe is the second-largest market for Artificial Pancreas Device Systems, accounting for approximately 30% of the global market share. The region is witnessing a surge in diabetes cases, prompting increased demand for effective management solutions. Regulatory frameworks, such as the EU Medical Device Regulation, are facilitating the introduction of innovative products, thereby enhancing market growth prospects. Germany, France, and the UK are leading countries in this market, with significant contributions from companies like Roche Diabetes Care and Ypsomed. The competitive landscape is marked by a mix of established players and emerging startups, fostering innovation. Collaborative efforts between healthcare providers and technology firms are also driving advancements in device functionality and patient outcomes.

Asia-Pacific : Rapidly Growing Market Segment

Asia-Pacific is an emerging powerhouse in the Artificial Pancreas Device System market, holding about 20% of the global market share. The region is experiencing a rapid increase in diabetes cases, driven by urbanization, lifestyle changes, and an aging population. Government initiatives aimed at improving healthcare access and technology adoption are further propelling market growth, making it a focal point for investment and innovation. Countries like China, Japan, and India are at the forefront, with a growing number of local and international players entering the market. The competitive landscape is evolving, with companies like Abbott Laboratories and Tandem Diabetes Care expanding their presence. The region's diverse healthcare needs and increasing awareness of diabetes management solutions are creating significant opportunities for growth and development in this sector.

Middle East and Africa : Untapped Market with Potential

The Middle East and Africa region represents a nascent market for Artificial Pancreas Device Systems, holding approximately 5% of the global market share. The region faces significant challenges, including a rising diabetes prevalence and limited access to advanced healthcare technologies. However, increasing government initiatives aimed at improving healthcare infrastructure and awareness are beginning to drive demand for innovative diabetes management solutions. Countries like South Africa and the UAE are leading the way in adopting new technologies, with a growing interest from international players. The competitive landscape is still developing, with opportunities for local manufacturers to enter the market. As healthcare systems evolve and patient awareness increases, the potential for growth in this region is substantial, making it an area of interest for future investments.

Artificial Pancreas Device System Market Regional Image

Key Players and Competitive Insights

The Artificial Pancreas Device System Market is experiencing significant growth, driven by advancements in diabetes management technologies and increasing awareness among patients and healthcare providers about the benefits of these innovative solutions. As diabetes prevalence rises globally, the demand for automated systems that can enhance glycemic control and improve the quality of life for patients is becoming more pronounced. Competitive insights reveal that numerous players are focusing on product development, strategic collaborations, and market entry to capture a larger share of this evolving market. Key factors influencing the competitive landscape include technological advancements, regulatory approvals, and the overall efficacy of the devices. The landscape is marked by intense competition, with established companies and new entrants striving to innovate and enhance their offerings to meet the diverse needs of diabetic patients. Sanofi has established a strong presence in the Artificial Pancreas Device System Market, leveraging its expertise in diabetes care and innovative technology. The company’s strategic initiatives focus on developing effective solutions that integrate seamlessly with existing diabetes management practices. Sanofi has made significant investments in research and development to enhance its product pipeline, ensuring that its artificial pancreas systems are not only technologically advanced but also user-friendly. Their commitment to improving patient outcomes, alongside a robust understanding of market dynamics, positions Sanofi favorably against competitors. Moreover, the company is actively involved in partnerships and collaborations aimed at broadening its product reach and addressing the complexities associated with diabetes care, thereby enhancing its market standing significantly. Eli Lilly is another key player in the Artificial Pancreas Device System Market, recognized for its dedication to diabetes management solutions. The company has developed a range of innovative products that cater to the growing demand for automated insulin delivery systems. Eli Lilly's strengths lie in its extensive research capabilities and strong focus on clinical trials, which are crucial in demonstrating the efficacy and safety of its products. By leveraging its established reputation in diabetes care, Eli Lilly continues to forge strategic alliances with technology firms to enhance its artificial pancreas systems. These collaborations enable the integration of cutting-edge technology into their devices, promoting better health outcomes for patients. Eli Lilly's proactive approach to addressing the multifaceted challenges associated with diabetes management enables it to maintain a competitive edge in the market, positioning the company as a leader in this crucial segment of healthcare innovation.

Key Companies in the Artificial Pancreas Device System Market include

Industry Developments

Recent developments in the Artificial Pancreas Device System Market indicate a heightened focus on innovation and collaboration among key industry players. Sanofi and Abbott have made strides in developing advanced solutions aimed at improving diabetes management, while Eli Lilly continues to enhance its product offerings for better patient adherence. Boehringer Ingelheim's strategic partnerships with technology firms aim to integrate data analytics into their devices, which could significantly enhance their functionality. TypeZero Technologies has garnered attention for its software that optimizes insulin delivery, collaborating with major companies like Tandem Diabetes Care and Insulet. 

A notable merger in the market recently involves Medtronic's acquisition of a tech startup focused on AI-driven diabetes management solutions, further solidifying its market position. Meanwhile, Dexcom and Roche are expanding their product portfolios to include more advanced continuous glucose monitoring systems, reflecting the growing demand for integrated and user-friendly diabetes care options. This changing landscape, characterized by mergers, acquisitions, and innovations, boosts the market valuation as companies adapt to meet the evolving needs of diabetes patients around the world.

Future Outlook

Artificial Pancreas Device System Market Future Outlook

The Artificial Pancreas Device System Market is projected to grow at a 19.72% CAGR from 2025 to 2035, driven by technological advancements, increasing diabetes prevalence, and rising demand for automated solutions.

New opportunities lie in:

  • Development of integrated telehealth platforms for remote monitoring and support. Expansion into emerging markets with tailored pricing strategies. Collaboration with pharmaceutical companies for combined therapy solutions.

By 2035, the market is expected to achieve substantial growth, positioning itself as a leader in diabetes management solutions.

Market Segmentation

Artificial Pancreas Device System Market Type Outlook

  • Fully Automated
  • Semi-Automated
  • Transcutaneous

Artificial Pancreas Device System Market End User Outlook

  • Hospitals
  • Home Care Settings
  • Diabetes Clinics

Artificial Pancreas Device System Market Component Outlook

  • Glucose Sensor
  • Insulin Pump
  • Control Algorithm

Artificial Pancreas Device System Market Technology Outlook

  • Closed Loop Systems
  • Open Loop Systems
  • Hybrid Systems

Report Scope

MARKET SIZE 2024 1.233(USD Billion)
MARKET SIZE 2025 1.476(USD Billion)
MARKET SIZE 2035 8.93(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR) 19.72% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Billion
Key Companies Profiled Medtronic (US), Insulet Corporation (US), Tandem Diabetes Care (US), Roche Diabetes Care (DE), Dexcom (US), Abbott Laboratories (US), Ypsomed (CH), AstraZeneca (GB), Boehringer Ingelheim (DE)
Segments Covered Types, Component, End Users, Technology, Regional
Key Market Opportunities Advancements in closed-loop systems enhance diabetes management, driving growth in the Artificial Pancreas Device System Market.
Key Market Dynamics Technological advancements and regulatory support drive innovation and adoption in the Artificial Pancreas Device System market.
Countries Covered North America, Europe, APAC, South America, MEA

Market Highlights

FAQs

What is the projected market valuation of the Artificial Pancreas Device System by 2035?

The projected market valuation for the Artificial Pancreas Device System is expected to reach 8.93 USD Billion by 2035.

What was the market valuation of the Artificial Pancreas Device System in 2024?

The overall market valuation of the Artificial Pancreas Device System was 1.233 USD Billion in 2024.

What is the expected CAGR for the Artificial Pancreas Device System Market from 2025 to 2035?

The expected CAGR for the Artificial Pancreas Device System Market during the forecast period 2025 - 2035 is 19.72%.

Which companies are considered key players in the Artificial Pancreas Device System Market?

Key players in the market include Medtronic, Insulet Corporation, Tandem Diabetes Care, Roche Diabetes Care, Dexcom, Abbott Laboratories, Ypsomed, AstraZeneca, and Boehringer Ingelheim.

What are the market segments for the Artificial Pancreas Device System by type?

The market segments by type include Fully Automated, Semi-Automated, and Transcutaneous systems, with valuations ranging from 0.5 to 3.5 USD Billion for Fully Automated.

How do the components of the Artificial Pancreas Device System market perform?

The components include Glucose Sensors, Insulin Pumps, and Control Algorithms, with Insulin Pumps valued at 0.4932 to 3.65 USD Billion.

What are the end-user segments for the Artificial Pancreas Device System?

End-user segments include Hospitals, Home Care Settings, and Diabetes Clinics, with Hospitals valued at 0.493 to 3.56 USD Billion.

What technologies are utilized in the Artificial Pancreas Device System?

Technologies in the market include Closed Loop Systems, Open Loop Systems, and Hybrid Systems, with Closed Loop Systems valued at 0.5 to 3.5 USD Billion.

How does the market for Artificial Pancreas Device Systems compare to previous years?

The market has shown substantial growth from 1.233 USD Billion in 2024, indicating a robust upward trajectory.

What factors contribute to the growth of the Artificial Pancreas Device System Market?

Factors contributing to growth include technological advancements, increasing diabetes prevalence, and the rising demand for automated insulin delivery systems.

Author
Author
Author Profile
Rahul Gotadki LinkedIn
Research Manager
He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.
Get In Touch
Leave a Comment

Research Approach

Secondary Research

The secondary research process involved rigorous analysis of regulatory filings, clinical trial repositories, diabetes epidemiology databases, and authoritative endocrinology institutions. Key sources included the US Food & Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) Premarket Approval (PMA) and 510(k) databases, European Medicines Agency (EMA) medical device regulations, Health Canada Medical Devices Directorate, Pharmaceuticals and Medical Devices Agency (PMDA) Japan, and National Medical Products Administration (NMPA) China. Clinical and epidemiological data were gathered from the International Diabetes Federation (IDF) Diabetes Atlas (10th Edition), Centers for Disease Control and Prevention (CDC) National Diabetes Statistics Report, National Institutes of Health (NIH) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) repository, and PubMed/MEDLINE for peer-reviewed trials on hybrid closed-loop systems (Control-IQ, MiniMed 780G, Omnipod 5). Professional societies contributing data included the American Diabetes Association (ADA) Standards of Medical Care, European Association for the Study of Diabetes (EASD), Endocrine Society, and Juvenile Diabetes Research Foundation (JDRF) Artificial Pancreas Project consortium. Reimbursement and health technology assessment sources comprised the Centers for Medicare & Medicaid Services (CMS) National Coverage Determinations for Continuous Glucose Monitors (CGM) and insulin pumps, NHS England Specialized Commissioning, and German Institute for Quality and Efficiency in Health Care (IQWiG).

Device approval timelines, clinical efficacy endpoints (Time-in-Range, HbA1c reduction), diabetes prevalence/incidence statistics by Type 1/Type 2, and payor coverage policies for automated insulin delivery (AID) systems were all provided by these sources.

Primary Research

In order to obtain qualitative insights regarding technology adoption barriers and quantitative data regarding installed base volumes, interviews were conducted with supply-side and demand-side stakeholders during the primary research project. The supply-side sources consisted of Chief Executive Officers, Vice Presidents of Research & Development, regulatory affairs directors, and clinical affairs managers from insulin pump developers, continuous glucose monitor manufacturers, and closed-loop algorithm software companies. Demand-side sources included procurement officers from tertiary care hospitals, ambulatory surgical centers, and home healthcare agencies, as well as board-certified endocrinologists, diabetologists, and certified diabetes care and education specialists (CDCES). Primary research has confirmed pipeline timelines for dual-hormone artificial pancreas development and has gathered insights on patient selection criteria, reimbursement navigation, and competitive switching dynamics between integrated and non-integrated pump-CGM systems. Additionally, market segmentation has been validated across threshold suspend, predictive low glucose suspend (PLGS), hybrid closed-loop (HCL), and bihormonal systems.

Primary Respondent Breakdown:

By Designation: C-level Primaries (30%), Director Level (35%), Others (35%)

By Region: North America (32%), Europe (30%), Asia-Pacific (28%), Rest of World (10%)

Market Size Estimation

Device shipment tracking and patient-on-therapy analysis were employed to determine the global market valuation for Type 1 and insulin-requiring Type 2 diabetes populations. The methodology comprised the following:

The identification of over 25 key manufacturers in North America, Europe, Asia-Pacific, and the Middle East and Africa who specialize in sensor-augmented pumps, controller algorithms, and dual-chamber delivery systems.

Product mapping spanning device control generations (threshold suspend, PLGS, hybrid closed-loop, bionic pancreas/bihormonal) and component categories (CGM transmitters, insulin pumps, infusion systems, docking controllers)

Analysis of quarterly revenues that are specific to automated insulin delivery portfolios and standalone CGM/pump integration partnerships, as reported and modeled

The high market concentration in regulated medical devices is accounted for by the coverage of manufacturers that represent 75-80% of the global market share in 2024.

Extrapolation using bottom-up (patient starts on closed-loop therapy × device ASP by reimbursement market; CGM transmitter replacement cycles × consumable pricing) and top-down (public company diabetes care segment revenue validation, calibrated against IDF diabetes population estimates by country) approaches to derive segment-specific valuations for hospital versus homecare settings

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

No regional reports available for this market.

Customer Stories
Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓